Acorda Therapeutics (ACOR) Tops Q1 EPS by 38c, Revenues Beat

Acorda Therapeutics (NASDAQ: ACOR) reported Q1 EPS of ($0.56), $0.38 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $44.14 million versus the consensus estimate of $33.04 million.

“Since INBRIJA became commercially available at the end of February, the feedback from both healthcare professionals and people with Parkinson’s, or PWPs, has been enthusiastic, and our Prescription Support Services center has received approximately 2,000 prescription requests. Our market research has consistently shown that both physicians and PWPs consider OFF periods one of the most troubling and disruptive aspects of Parkinson’s, and that they regard INBRIJA as having the potential to address this significant unmet need,” said Ron Cohen, M.D., Acorda\'s President and CEO. “We are currently meeting with insurers to discuss formulary placement. We are also continuing to roll out in-person and digital programs to educate healthcare professionals and PWPs about INBRIJA.”

2019 Financial Guidance

• During INBRIJA’s launch year, the Company does not expect to provide INBRIJA revenue guidance.
• The Company will no longer provide revenue guidance for AMPYRA, due to the unpredictable trajectory of revenue decline given the entrance of generics.
• R&D expenses for the full year 2019 are expected to be $70-$80 million and SG&A expenses for the full year 2019 are expected to be $200-$210 million. This guidance is a non-GAAP projection that excludes share-based compensation as more fully described below under “Non-GAAP Financial Measures.”

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Palogic urges Granite Point Mortgage to cut costs, halt new loans
• Xylem names Andrea van der Berg as CFO, effective Sept. 2026